PortalPublikationenTranscatheter aortic valve implantation with different self-...

Transcatheter aortic valve implantation with different self-expanding devices-a propensity score-matched multicenter comparison

Standard

Transcatheter aortic valve implantation with different self-expanding devices-a propensity score-matched multicenter comparison. / Wienemann, Hendrik; Hof, Alexander; Ludwig, Sebastian; Veulemans, Verena; Sedaghat, Alexander; Iliadis, Christos; Meertens, Max; Macherey, Sascha; Hohmann, Christopher; Kuhn, Elmar; Al-Kassou, Baravan; Wilde, Nihal; Schofer, Niklas; Bleiziffer, Sabine; Maier, Oliver; Kelm, Malte; Baldus, Stephan; Rudolph, Tanja Katharina; Adam, Matti; Mauri, Victor.

in: HELL J CARDIOL, Jahrgang 70, 2023, S. 1-9.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wienemann, H, Hof, A, Ludwig, S, Veulemans, V, Sedaghat, A, Iliadis, C, Meertens, M, Macherey, S, Hohmann, C, Kuhn, E, Al-Kassou, B, Wilde, N, Schofer, N, Bleiziffer, S, Maier, O, Kelm, M, Baldus, S, Rudolph, TK, Adam, M & Mauri, V 2023, 'Transcatheter aortic valve implantation with different self-expanding devices-a propensity score-matched multicenter comparison', HELL J CARDIOL, Jg. 70, S. 1-9. https://doi.org/10.1016/j.hjc.2022.12.006

APA

Wienemann, H., Hof, A., Ludwig, S., Veulemans, V., Sedaghat, A., Iliadis, C., Meertens, M., Macherey, S., Hohmann, C., Kuhn, E., Al-Kassou, B., Wilde, N., Schofer, N., Bleiziffer, S., Maier, O., Kelm, M., Baldus, S., Rudolph, T. K., Adam, M., & Mauri, V. (2023). Transcatheter aortic valve implantation with different self-expanding devices-a propensity score-matched multicenter comparison. HELL J CARDIOL, 70, 1-9. https://doi.org/10.1016/j.hjc.2022.12.006

Vancouver

Wienemann H, Hof A, Ludwig S, Veulemans V, Sedaghat A, Iliadis C et al. Transcatheter aortic valve implantation with different self-expanding devices-a propensity score-matched multicenter comparison. HELL J CARDIOL. 2023;70:1-9. https://doi.org/10.1016/j.hjc.2022.12.006

Bibtex

@article{7125de1f167949c59c3c283ca72026f5,
title = "Transcatheter aortic valve implantation with different self-expanding devices-a propensity score-matched multicenter comparison",
abstract = "OBJECTIVE: Several supra-annular self-expanding transcatheter systems are commercially available for transcatheter aortic valve implantation (TAVI). Comparative data in large-scale multicenter studies are scant.METHODS: This study included a total of 5175 patients with severe aortic stenosis undergoing TAVI with the ACURATE neo (n = 1095), Evolut R (n = 3365), or Evolut PRO (n = 715) by a transfemoral approach at five high-volume centers. Propensity score matching resulted in 654 triplets. Outcomes are reported according to the Valve Academic Research Consortium-3 (VARC-3) consensus.RESULTS: Moderate or severe paravalvular regurgitation (PVR) occurred significantly more often in the ACURATE neo group (5.2%) than in the Evolut R (1.8%) and Evolut PRO (3.3%) groups (p = 0.003). The rates of major vascular-/access-related complications (4.6%, 3.8%, and 5.0%; p = 0.56), type 3 or 4 bleeding (3.2%, 2.1%, and 4.1%; p = 0.12), and 30-day mortality (2.4%, 2.6%, and 3.7%; p = 0.40) were comparable. The rate of new permanent pacemaker implantation (PPI) was significantly lower in the ACURATE neo group (9.5%, 17.6%, and 16.8%; p < 0.001). Independent predictors for 2-year survival were a Society of Thoracic Surgeons (STS) risk score ≥5%, diabetes mellitus, a glomerular filtration rate <30 ml/min, baseline mean transvalvular gradient ≤ 30 mm Hg, treating center, and relevant PVR.CONCLUSION: In this multicenter study, TAVI with the ACURATE neo, Evolut R, or Evolut PRO was feasible and safe. The rate of relevant PVR was more frequent after the ACURATE neo implantation, with, however, lower rates of PPI. Two-year survival was mainly driven by baseline comorbidities.",
author = "Hendrik Wienemann and Alexander Hof and Sebastian Ludwig and Verena Veulemans and Alexander Sedaghat and Christos Iliadis and Max Meertens and Sascha Macherey and Christopher Hohmann and Elmar Kuhn and Baravan Al-Kassou and Nihal Wilde and Niklas Schofer and Sabine Bleiziffer and Oliver Maier and Malte Kelm and Stephan Baldus and Rudolph, {Tanja Katharina} and Matti Adam and Victor Mauri",
note = "Copyright {\textcopyright} 2022 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.",
year = "2023",
doi = "10.1016/j.hjc.2022.12.006",
language = "English",
volume = "70",
pages = "1--9",
journal = "HELL J CARDIOL",
issn = "1109-9666",
publisher = "Hellenic Cardiological Society",

}

RIS

TY - JOUR

T1 - Transcatheter aortic valve implantation with different self-expanding devices-a propensity score-matched multicenter comparison

AU - Wienemann, Hendrik

AU - Hof, Alexander

AU - Ludwig, Sebastian

AU - Veulemans, Verena

AU - Sedaghat, Alexander

AU - Iliadis, Christos

AU - Meertens, Max

AU - Macherey, Sascha

AU - Hohmann, Christopher

AU - Kuhn, Elmar

AU - Al-Kassou, Baravan

AU - Wilde, Nihal

AU - Schofer, Niklas

AU - Bleiziffer, Sabine

AU - Maier, Oliver

AU - Kelm, Malte

AU - Baldus, Stephan

AU - Rudolph, Tanja Katharina

AU - Adam, Matti

AU - Mauri, Victor

N1 - Copyright © 2022 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.

PY - 2023

Y1 - 2023

N2 - OBJECTIVE: Several supra-annular self-expanding transcatheter systems are commercially available for transcatheter aortic valve implantation (TAVI). Comparative data in large-scale multicenter studies are scant.METHODS: This study included a total of 5175 patients with severe aortic stenosis undergoing TAVI with the ACURATE neo (n = 1095), Evolut R (n = 3365), or Evolut PRO (n = 715) by a transfemoral approach at five high-volume centers. Propensity score matching resulted in 654 triplets. Outcomes are reported according to the Valve Academic Research Consortium-3 (VARC-3) consensus.RESULTS: Moderate or severe paravalvular regurgitation (PVR) occurred significantly more often in the ACURATE neo group (5.2%) than in the Evolut R (1.8%) and Evolut PRO (3.3%) groups (p = 0.003). The rates of major vascular-/access-related complications (4.6%, 3.8%, and 5.0%; p = 0.56), type 3 or 4 bleeding (3.2%, 2.1%, and 4.1%; p = 0.12), and 30-day mortality (2.4%, 2.6%, and 3.7%; p = 0.40) were comparable. The rate of new permanent pacemaker implantation (PPI) was significantly lower in the ACURATE neo group (9.5%, 17.6%, and 16.8%; p < 0.001). Independent predictors for 2-year survival were a Society of Thoracic Surgeons (STS) risk score ≥5%, diabetes mellitus, a glomerular filtration rate <30 ml/min, baseline mean transvalvular gradient ≤ 30 mm Hg, treating center, and relevant PVR.CONCLUSION: In this multicenter study, TAVI with the ACURATE neo, Evolut R, or Evolut PRO was feasible and safe. The rate of relevant PVR was more frequent after the ACURATE neo implantation, with, however, lower rates of PPI. Two-year survival was mainly driven by baseline comorbidities.

AB - OBJECTIVE: Several supra-annular self-expanding transcatheter systems are commercially available for transcatheter aortic valve implantation (TAVI). Comparative data in large-scale multicenter studies are scant.METHODS: This study included a total of 5175 patients with severe aortic stenosis undergoing TAVI with the ACURATE neo (n = 1095), Evolut R (n = 3365), or Evolut PRO (n = 715) by a transfemoral approach at five high-volume centers. Propensity score matching resulted in 654 triplets. Outcomes are reported according to the Valve Academic Research Consortium-3 (VARC-3) consensus.RESULTS: Moderate or severe paravalvular regurgitation (PVR) occurred significantly more often in the ACURATE neo group (5.2%) than in the Evolut R (1.8%) and Evolut PRO (3.3%) groups (p = 0.003). The rates of major vascular-/access-related complications (4.6%, 3.8%, and 5.0%; p = 0.56), type 3 or 4 bleeding (3.2%, 2.1%, and 4.1%; p = 0.12), and 30-day mortality (2.4%, 2.6%, and 3.7%; p = 0.40) were comparable. The rate of new permanent pacemaker implantation (PPI) was significantly lower in the ACURATE neo group (9.5%, 17.6%, and 16.8%; p < 0.001). Independent predictors for 2-year survival were a Society of Thoracic Surgeons (STS) risk score ≥5%, diabetes mellitus, a glomerular filtration rate <30 ml/min, baseline mean transvalvular gradient ≤ 30 mm Hg, treating center, and relevant PVR.CONCLUSION: In this multicenter study, TAVI with the ACURATE neo, Evolut R, or Evolut PRO was feasible and safe. The rate of relevant PVR was more frequent after the ACURATE neo implantation, with, however, lower rates of PPI. Two-year survival was mainly driven by baseline comorbidities.

U2 - 10.1016/j.hjc.2022.12.006

DO - 10.1016/j.hjc.2022.12.006

M3 - SCORING: Journal article

C2 - 36538975

VL - 70

SP - 1

EP - 9

JO - HELL J CARDIOL

JF - HELL J CARDIOL

SN - 1109-9666

ER -